Dexcom continues to offer its leading CGM systems, along with Stelo, its recently launched over-the-counter glucose biosensor. Combining its OTC CGM offering with the retail-available Oura Ring ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

The FDA has cleared Dexcom’s Stelo as the first continuous glucose monitoring (CGM) device that does not need a prescription, which can be used by diabetics on oral medications, as well as non ...

Investing.com -- DexCom Inc (NASDAQ:DXCM) shares up more than 2% following updated guidelines by the American Diabetes Association (ADA), which now recommend using continuous glucose monitors ...

Medical device specialist DexCom (NASDAQ: DXCM) is going through a rough patch. The company's shares are down sharply year to date due to unimpressive financial results -- and some of the ...

Smart ring maker Oura announced on Tuesday that it has received a $75 million investment from glucose device maker Dexcom. The investment marks Oura’s Series D funding round and brings the ...

Oura is partnering with medical device maker Dexcom to integrate data from glucose biosensors with the Oura Ring, which tracks sleep, heart rate and activity. Oura also picked up $75 million from ...